Results 181 to 190 of about 58,249 (234)

Induction of colistin resistance and environmental toxicity assessment in Escherichia coli. [PDF]

PLoS One
Nunes Lima TH, de Souza M, Soares JM, Blanco KC, Salvador Bagnato EV.   +4 more
europepmc   +1 more source

Suboptimal ceftazidime-avibactam exposure drives sequential <i>bla</i>_KPC mutations and intra-host coexistence of <i>Klebsiella pneumoniae</i> harboring distinct variants leading to persistent infection. [PDF]

Microbiol Spectr
Yang F, Yang W, Zhang J, Tang C, Ding L, Shen S, Zhou Y, Zhao H, Zhou J, Hu F.   +9 more
europepmc   +1 more source

Clinical Efficacy and Safety of Multiple High-Dose Antibiotic-Loaded Cement Spacers in the Two-Stage Revision of Gram-Positive Periprosthetic Joint Infection. [PDF]

Microorganisms
Márquez-Gómez M, Prats-Peinado L, Díaz JAM, Sánchez-Somolinos M, Guembe M, Vaquero J, Sanz-Ruiz P.   +6 more
europepmc   +1 more source

KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]

PLoS One
Zhao S, Ye L, Song S, Sun J, Xu J, Jiang F, Kang H.   +6 more
europepmc   +1 more source

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. [PDF]

Antimicrob Agents Chemother
Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, Bulman ZP, Cosgrove SE, Simner PJ, Tamma PD.   +9 more
europepmc   +1 more source

Current progress in antibacterial agents for carbapenem-resistant enterobacterales. [PDF]

Front Pharmacol
Xu W, Shang L, Li X, Yu J, Shen J, Li Y, He Q, Chen L, Wang D, Wei Y, Niu S.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The pharmacy of ceftazidime

Journal of Antimicrobial Chemotherapy, 1981
The stability of ceftazidime for injection in the dry state and after reconstitution with water for injections was determined. Compatibility of ceftazidime for injection with lignocaine hydrochloride injection (1.0% w/v) and several commonly used intravenous fluids was tested, Ceftazidime for injection was found to be essentially stable in the dry ...
B L, Richardson, J D, Woodford, G D, Andrews   +2 more
openaire   +2 more sources

Ceftazidime Review

Drug Intelligence & Clinical Pharmacy, 1985
The chemistry, in vitro activity, adverse effects, and clinical indications for the new third-generation cephalosporin, ceftazidime, are reviewed. Ceftazidime appears to have a unique place among the third-generation agents in the treatment of some infectious processes caused by Pseudomonas aeruginosa. It does not demonstrate superiority to other third-
Richard L. Yost, Reuben Ramphal, Donald C. McLeod   +2 more
openaire   +2 more sources

Ceftazidime in septicaemia

Journal of Antimicrobial Chemotherapy, 1983
Thirty-five patients with mean age 70 years (range 22 to 92) with 37 proven episodes of septicaemia (26) or bacteraemia (11) were treated with a mean ceftazidime dose of 1.80 (range 1 to 2 g) bid for 12 (range 3 to 17) days. Twenty patients had underlying diseases. Escherichia coli was the most common pathogen (19/37).
P, Lundbergh, C, Jarstrand, L, Morfeldt-Månson, O, Weiland   +3 more
openaire   +2 more sources

Pulmonary Penetration of Ceftazidime

Journal of Chemotherapy, 1995
For an antibiotic to be effective in lower respiratory tract infections, it should be available in adequate concentrations in respiratory tissues and fluids. Cephalosporins usually achieve modest concentrations in the respiratory tract. In this study we have determined the pulmonary penetration of intramuscularly administered ceftazidime (a single dose
CAZZOLA M, GABRIELLA MATERA M, POLVERINO M, SANTANGELO G, DE FRANCHIS I, ROSSI, Francesco   +5 more
openaire   +3 more sources